Lower IGF-1 concentration associated with higher fracture risk...
Read More »Increase in Osteoporosis Thought Due to Increase in DPP-4
Postmenopausal women with normal glucose tolerance focus of study.
Read More »Ocular Examination for Children with Type 1 Diabetes
Screenings for diabetic retinopathy should begin at age 15 or 5 years after diagnosis....
Read More »Lifestyle Modifications with High-Intensity Exercise in Diabetes
Short periods of intense physical activity can improve heart structure and diabetes control...
Read More »Mortality Increased by 50% in Smokers with Diabetes
Active smoking is associated with significantly increased risks of total mortality and cardiovascular events...
Read More »How Type 2 Diabetes is Linked with Alzheimer’s Disease
T2 patients may be at increased risk of developing tangles in the brain that indicate dementia.
Read More »The Value of the Nitric Oxide Pathway and its Importance in African-American Patients with Heart Failure
Studies in heart failure and hypertension have shown that people who identify themselves as black may have a less active renin-angiotensin system and a lower bioavailability of nitric oxide. The A-HeFT study was conducted to determine if a fixed dose of isosorbide dinitrate (ISDN) and hydralazine would provide additional benefit in black patients with heart failure.
Read More »Discontinuation of TZD Reduces Fracture Rates
Thiazolidinediones (TZDs), rosiglitazone and pioglitazone, have been shown to increase fracture risk in women after a year of TZD use; however, there has been little data available on the effects of the discontinuation of TZD. This longitudinal observational cohort study used data from an ancillary study of skeletal health within …
Read More »Finerenone Improves Albuminuria in Diabetic Nephropathy Patients
Mineralocorticoid receptor antagonists (MRAs) are often used with a renin-angiotensin system (RAS) blocker to further reduce proteinuria in patients with CKD. However, eplerenone and spironolactone increase the risk of hyperkalemia in these patients. Finerenone (BAY94-8862) is a new nonsteroidal MRA that has better receptor selectivity than spironolactone, associating with lower …
Read More »FDA Warning: Invokana Can Increase Risk of Bone Fracture
Bone mineral density at hip and lower spine may also decrease.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.